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Purpose: To report an extremely rare case of tapioca melanoma of the iris in an Iranian patient.
Case Report: A 50-year-old male patient presented with ocular pain and redness in the right eye for two
weeks. The visual acuity was 7/10 and the intraocular pressure (IOP) was 30 mmHg. A lobulated amelanotic
vascularized and nodular (tapioca-like) iris mass with a 180o extent was seen in the right eye. Incisional
biopsy of the mass revealed atypical mixed type (epithelioid and spindle cell) melanoma. Brachytherapy
with the ruthenium-106 plaque resulted in complete regression of the tumor.
Conclusion: Tapioca melanoma of the iris should be considered in the differential diagnosis of patients
presenting with nodular vascularized amelanotic iris mass and elevated IOP. Brachytherapy with ruthenium-
106 seems to be an effective treatment for tapioca melanoma of the iris.
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INTRODUCTION
Tapioca melanoma of the iris is a rare form of
diffuse iris melanoma,[1, 2] typically presenting with
heterochromia and elevated intraocular pressure
(IOP), mainly because of aqueous outflow block-
ade. This tumor could also manifest as a diffuse,
circumferential, and lightly pigmented or amelan-
otic lesion.[3, 4] Almost 3–5% of patients develop
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distant metastasis of tumor.[5] Histopathologi-
cally, tapioca melanoma is similar to other types of
iris melanomas, but can be distinguished by their
specific clinical presentations.[6]
Tapioca melanoma is characterized by weakly
pigmented spindle or epithelioid malignant
cells with a spreading pattern.[3, 4] Compared
to the other types of iris melanomas, tapioca
melanoma is an uncommon type characterized
by seeding and high IOP in younger patients.[5]
A collection of epithelioid cells in the anterior
chamber angle may cause glaucoma.[4] The
S-100 is a strong marker for diagnosis of
cutaneous melanoma, but iris melanomas
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Figure 1. Primary presentation: Conjunctiva and ciliary injec-
tion of the right eye.
Figure 2. Amelanotic, nodular, and vascularized iris mass with
prominent feeder vessels.
Figure 3. High resolution ultrasound biomicroscope shows
diffuse thickening and infiltration of iris with the tumor.
have diverse morphologies and different abili-
ties to take up this stain. Therefore, diagnosis
of atypical iris melanomas may be difficult and
challenging.[2, 7] Early diagnosis and treatment of
atypical iris melanomas are essential for preventing
the progression of the disease and saving the
patients’ eyesight and life.[8, 9]
CASE REPORT
A 50-year-old male patient presented with ocu-
lar pain and redness in the right eye for two
weeks. The best-corrected visual acuity was 7/10
and 9/10 in the right and left eyes, respectively,
Figure 4. Enlarged vascularized iris mass, two weeks after first
visit.
Figure 5. Ru-106 plaque (CIA design) to treat the iris tapioca
melanoma.
without afferent pupillary defect. Extraocular move-
ments were within normal limits in both eyes.
Except for controlled diabetes mellitus, the past
medical and surgical history were unremarkable.
Slit lamp examination revealed “1+” cells in the
anterior chamber and fine keratic precipitates on
the corneal endothelium. There was a lobulated,
nodular, amelanotic, and highly vascularized mass
measuring about four clock hours of the iris
nasally, disrupting the normal iris structure [Figures
1 and 2]. The IOP was 16 and 15 mmHg in the
right and left eyes, respectively. Dilated fundus
examination and optical coherence tomography
images revealed moderate non-proliferative dia-
betic retinopathy without diabetic macular edema
in both eyes. Ultrasound biomicroscopy (UBM)
determined diffuse iris thickening (2.02 mm) and
tumoral involvement of the iris with minimal spread
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Figure 6. Histopathologic images (a) Epithelioid and spindle-shaped neoplastic cells with apoptotic bodies and mild scattered
melanin pigments [hematoxylin and eosin stain (H&E)×400]; (b,c)-Dysplastic tumor cellsmainly of epithelioid typewith large nuclei,
prominent nucleoli, and apoptosis, H&E ×1000, higher magnification; Patchy immune-reactivity to HMB45 (d), strong immune-
reactivity to S100 (e) and Ki67 (f), magnification ×400; (g) Patchy immune-reactivity to melan-A, magnification ×400.
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Figure 7. High resolution ultrasound biomicroscopy (UBM) of
the iris, five months after brachytherapy with ru-106 plaque
reveals complete tumor regression and iris atrophy.
Figure 8. Photo-slit image of the right eye five months after
treatment: Complete tumor regression, iris atrophy, localized
posterior synechia, and mild cataract noted.
to the ciliary body [Figure 3]. Systemic work-
up tested negative for metastasis, granulomatous
diseases, or any extraocular primary tumor. Two
weeks later, ocular pain and redness increased,
the IOP peaked at 30 mmHg, and the mass grew
and involved the six o’clock region of the iris
[Figure 4]. With the provisional diagnosis of iris
tapioca melanoma, incisional biopsy of the iris and
brachytherapy with ruthenium-106 CIA radioactive
plaque (Eckert & Ziegler BEBIG GmbH, 100 Gy,
Berlin, Germany) were performed simultaneously
[Figure 5]. Microscopic examination of the biopsied
tissue demonstrated atypical epithelioid and spin-
dle cells with large nuclei and prominent nucleoli
with melanin pigments [Figure 6]. There was a
strong immunoreactivity to S-100 and Ki-67 and
patchy immunoreactivity to HMB45 and melan-A.
All examinations revealed a rare subtype of iris
malignant melanoma called tapioca melanoma. No
metastasis was found in the systemic work-up.
One week after treatment, the tumor regressed,
and IOP decreased to 14 mmHg. Five months
after brachytherapy, there was no sign of tumor
recurrence or metastasis. Slit lamp examination
and UBM demonstrated complete tumor regres-
sion with iris atrophy and mild lens opacity [Figures
7 and 8].
DISCUSSION
Tapioca melanoma, a rare form of diffuse iris
melanoma presenting as a hyperchromic iris
heterochromia with unilateral elevation of IOP due
to the aqueous outflow obstruction.[4] It seems that
agglomeration of epithelioid cells in the anterior
chamber angle is the cause of IOP elevation.[3]
Tapioca is derived from a native Brazilian word
denoting the pale granular starchmaterial obtained
from manioc tubers.[6] Algernon Reese used the
term “tapioca melanoma” for the first time in
1972, owing to the resemblance of these pale
tumor nodules to tapioca pudding.[2, 3, 10] Ear-
lier in 1959, Lorenz E Zimmerman diagnosed
this lesion and described it as an atypical iris
melanoma.[3] Compared to the other types of iris
melanoma, tapioca melanoma mostly occurs in
younger patients.[1] The youngest reported case
was that of a seven-year-old patient.[3] There could
be a connection between the inception of hor-
monal changes at puberty and the commence-
ment of uveal melanoma.[11] The mean age of
surgery in tapioca melanoma patients was 30
years, whereas in other types of iris melanoma
it was 46.[3] Our patient was 50 years old, but
remarkably, this rare type of melanoma is very
uncommon in adults. Different presentations of
tapioca iris melanoma in different populations may
be related to the varying genomic types of the
disease.[12]
There are several predisposing factors of uveal
melanoma, including ocular melanocytosis, neu-
rofibromatosis type 1, dysplastic nevus syndrome,
and familial uveal melanoma.[11] However, there was
no remarkable family history for uveal melanoma in
this case. This tumor usually presents as a vascular-
ized mass with nodular surface.[6] Diseases such as
Fuch’s heterochromic iridocyclitis, neurofibromato-
sis, and Cogan-Reesemay present with iris nodules
and elevated IOP.[1] In neurofibromatosis, there are
yellow-brown dome-shaped papules on the iris
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called Lisch nodules, while Cogan-Reese presents
irregular corneal endothelium with pedunculated
and pigmented nodules. In sarcoidosis, patients
have systemic signs and symptoms along with
papillitis, papilledema, and granulomas in any part
of the eye.[13] Juvenile xantogranuloma, Lisch and
Koeppe nodules, infectious granulomas, vascular
tumors, leiomyoma, metastases, and iris nevus
syndrome are some of the relevant differential
diagnosis.[8, 12] Due to the rarity of tapioca iris
melanoma, there are no well-defined criteria for
the identification of this type of tumor, and hence
its diagnosis can be challenging. Although the iris
tumor in our case may not have had the exact
appearance of a typical tapioca-like iris melanoma,
it could be classified as a tapioca iris melanoma
considering its characteristic iris nodules, anterior
uveitis, rapid growth, high IOP, and high rate of
vascularization. Immunohistochemical staining is
often used to confirm the diagnosis. S-100 marker
is usually used to stain melanoma and neural
tissues, while Ki-67 and HMB-45 are used to
mark proliferating cells.[1, 8] In the present case,
immunostainingwas positive for S-100, HMB-45, Ki-
67, and melan-A that confirmed the diagnosis of iris
melanoma.
There is no agreement on the specific size of iris
tumor for surgical treatment. Some authors believe
in tumor excision for lesions > 3 mm in diameter
or 1 mm in thickness.[13] Sectoral iridectomy is
advocated in patients with localized tumors that are
limited to the iris without satellite lesions, while en
bloc excision is recommended when the anterior
chamber angle is involved.[9]
Leiden used ruthenium-106 plaque brachyther-
apy to treat the iris and anterior ciliary body
melanomas for the first time in 1997.[14] Only two
recurrences were observed among 36 patients
with anterior uveal melanoma during the six and
a half years of follow-up. Ruthenium-106 plaques
are 𝛽-emitter sources. Therefore, the optic disc and
macula are exposed to lower doses of radiation
as compared to the 𝛽-emitter sources like I-125
plaques. [15] Ruthenium-106 plaque treatment for
iris melanoma has a significant effect on the
control of tumor without any recurrence.[16] Our
patient was treated with ruthenium-106 CIA plaque,
and there was complete regression of the tumor
without any recurrence after 18 months of follow-
up.
In conclusion, tapioca iris melanoma should be
considered in differential diagnosis of any iris tumor
presenting as a nodular vascularized iris mass and
elevated IOP.[1] Brachytherapy with ruthenium-106
plaque would be a useful treatment for tapioca iris
melanoma.
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